Job Trends
Bristol Myers Squibb and bluebird bio said data from the Phase II KarMMa study evaluating the safety and efficacy of ide-cel (idecabtagene vicleucel) met the primary endpoint of overall survival and the key secondary endpoint of complete response rate.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
THE LATEST
Company to host conference call today at 8:30am ET
The number of life science jobs grew by 12,500 for an approximate total of a total estimated employment of 311,226. That was music to the ears of Sara Radcliffe, president and chief executive officer of the California Life Sciences Association.
Viking Ninja joins growing roster of influential fitness and lifestyle influencers
ACG will be exhibiting its wide range of Engineering and Capsules solutions at this year’s Supply Side West, Las Vegas.
Crucial Data Solutions announces the latest update to their native mobile app for clinical trial data collection and management. TrialKit™, an eClinical platform, has incorporated Apple’s biometric technologies for user authentication.
Neos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 17,391,304 shares of its common stock at a price to the public of $2.30 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos.
Neos Therapeutics, Inc. today announced that it has commenced an underwritten public offering of its common stock
T-Cell Editor Creating the Powerful Immunotherapy Weapon
Neos Therapeutics, Inc. today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial markets on Friday, November 9, 2018.
New Data Demonstrate the Clinical Performance of the Prolaris® and myRisk® Hereditary Cancer Genetic Tests in Men with Prostate Cancer